BACKGROUND: This study assessed @entity137 , @entity5 response, disease control, and survival after short-course induction chemoradiotherapy and surgical resection in @entity1 with stage III @entity1149 . METHODS: Forty-five @entity1 with stage III @entity1149 received 12-day induction therapy of a 96-hour continuous infusion of @entity900 (20 mg/m2 per day), 24-hour infusion of @entity1311 (175 mg/m2), and concurrent accelerated fractionation radiation therapy (1.5 Gy twice daily) to a dose of 30 Gy. Surgical resection was scheduled for 4 weeks later. Postoperatively, a second identical course of chemotherapy and concurrent radiation therapy (30 to 33 Gy) was given. RESULTS: Induction @entity137 resulted in hospitalization of 18 (40%) @entity1 for @entity221 . No induction @entity204 occurred. Of 40 (89%) @entity1 who underwent thoracotomy, resection for cure was possible in 32 (71%) @entity1 . Pathologic response was noted in 21 (47%) @entity1 , and 14 (31%) were downstaged to mediastinal node negative (stage 0, I, or II). At a median follow-up of 19 months, 24 @entity1 were alive, 10 with recurrent disease. Of 21 @entity204 , 16 were from recurrent disease, three were from treatment, and two were unrelated. Recurrent disease was distant in 21 @entity1 , distant and locoregional in 2, and locoregional in 3. The Kaplan-Meier projected 24-month survival is 49%. Projected 24-month survival is 61% for stage IIIA, 17% for stage IIIB (p = 0.035); 84% for pathologic responders, 22% for nonresponders (p<0.001); 83% for downstaged @entity1 (stage 0, I, or II), 33% for those not downstaged (p = 0.005); and 63% for resectable @entity1 , 14% for unresectable @entity1 (p = 0.007). CONCLUSIONS: We conclude that short-course neoadjuvant therapy with @entity1311 (1) has manageable @entity137 and a low treatment mortality, (2) results in @entity5 response and downstaging, (3) provides excellent locoregional control with most recurrences being distant, and (4) has improved the median survival compared with historical controls. Survival was better in stage IIIA @entity1 , resectable @entity1 , pathologic responders, and @entity1 downstaged to mediastinal node negative disease (stage 0, I, or II).

Short-course induction chemoradiotherapy with @entity1311 for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'good tumor'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small-cell lung carcinoma'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity221 :: ('MESH:D005334', 'Disease') :: ['neutropenic fever']
@entity5 :: (MESH:D009369,Disease) :: ['stage III non-small-cell lung cancer']
